Last reviewed · How we verify
prasugrel / clopidogrel
prasugrel / clopidogrel is a P2Y12 receptor antagonist (thienopyridine) Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently FDA-approved for Acute coronary syndrome (unstable angina, NSTEMI, STEMI), Prevention of stent thrombosis following percutaneous coronary intervention, Secondary prevention of atherothrombotic events in patients with acute myocardial infarction.
Prasugrel and clopidogrel are both P2Y12 platelet adenosine diphosphate receptor antagonists that inhibit platelet aggregation and reduce thrombotic events.
Prasugrel and clopidogrel are both P2Y12 platelet adenosine diphosphate receptor antagonists that inhibit platelet aggregation and reduce thrombotic events. Used for Acute coronary syndrome (unstable angina, NSTEMI, STEMI), Prevention of stent thrombosis following percutaneous coronary intervention, Secondary prevention of atherothrombotic events in patients with acute myocardial infarction.
At a glance
| Generic name | prasugrel / clopidogrel |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | P2Y12 receptor antagonist (thienopyridine) |
| Target | P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Both drugs are thienopyridine class antiplatelet agents that irreversibly block the P2Y12 receptor on platelets, preventing ADP-induced platelet activation and aggregation. Prasugrel is a third-generation thienopyridine with faster onset and greater platelet inhibition compared to clopidogrel. They are used to reduce stent thrombosis and cardiovascular events in acute coronary syndromes and percutaneous coronary intervention.
Approved indications
- Acute coronary syndrome (unstable angina, NSTEMI, STEMI)
- Prevention of stent thrombosis following percutaneous coronary intervention
- Secondary prevention of atherothrombotic events in patients with acute myocardial infarction
Common side effects
- Bleeding (major and minor)
- Dyspnea
- Bradycardia
- Rash
- Thrombotic thrombocytopenic purpura (TTP)
Key clinical trials
- Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI (PHASE4)
- The Switching Antiplatelet-9 (SWAP-9) Study (PHASE4)
- Bariatric Surgery for the Reduction of cArdioVascular Events Randomized Controlled Trial (NA)
- ARCANGELO (itAlian pRospective Study on CANGrELOr)
- Aspirin and a PoTent P2Y12 Inhibitor Versus Aspirin and Clopidogrel in Patients Undergoing PCI for Complex Lesion (PHASE4)
- STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT (NA)
- VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome (PHASE4)
- Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- prasugrel / clopidogrel CI brief — competitive landscape report
- prasugrel / clopidogrel updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI
Frequently asked questions about prasugrel / clopidogrel
What is prasugrel / clopidogrel?
How does prasugrel / clopidogrel work?
What is prasugrel / clopidogrel used for?
Who makes prasugrel / clopidogrel?
What drug class is prasugrel / clopidogrel in?
What development phase is prasugrel / clopidogrel in?
What are the side effects of prasugrel / clopidogrel?
What does prasugrel / clopidogrel target?
Related
- Drug class: All P2Y12 receptor antagonist (thienopyridine) drugs
- Target: All drugs targeting P2Y12 receptor
- Manufacturer: Assistance Publique - Hôpitaux de Paris — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Acute coronary syndrome (unstable angina, NSTEMI, STEMI)
- Indication: Drugs for Prevention of stent thrombosis following percutaneous coronary intervention
- Indication: Drugs for Secondary prevention of atherothrombotic events in patients with acute myocardial infarction
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing